OTC Overhaul Shakes Big Pharma

Sign displaying the words BIG PHARMA on a glass building — BIG PHARMA SHAKEN

The FDA’s new leadership is floating a simple idea that would upend Big Pharma’s gatekeeping: most medicines should be over-the-counter unless they’re truly risky.

Quick Take

FDA Commissioner Marty Makary said drugs should default to OTC status unless they are unsafe, addictive, or require medical monitoring.
Makary tied the push to lower prices and better access by reducing dependence on insurers and pharmacy benefit managers (PBMs).
Industry groups cautioned that broad switches could raise out-of-pocket costs and increase misuse if “self-selection” fails.
The FDA has new tools and pathways to expand OTC access, but specific drug approvals and timelines remain unclear.

Makary’s “OTC by Default” Standard Targets Paternalism and Middlemen

FDA Commissioner Marty Makary outlined a deregulatory shift in a February 18, 2026, interview, arguing that medicines should be sold over the counter unless they are unsafe, addictive, or require monitoring.

Makary described the standard as moving from “why” a drug should be OTC to “why not,” emphasizing that patients can make routine decisions without a mandatory doctor visit. The approach also aims to route around high-cost intermediaries that shape prescription pricing.

FDA chief Marty Makary says 'everything should be over the counter' unless drug is unsafe or addictive https://t.co/HiYBuxvyWC

— Matthew Herper (@matthewherper) February 18, 2026

Makary framed expanded OTC availability as a way to lower consumer costs, especially when cash pricing can beat an insured copay that has been inflated by opaque pricing and PBM incentives.

The research material indicates his broader message aligns with Trump-era health agency deregulation and a “radical transparency” posture. As of February 18, however, the FDA had not announced a finalized list of specific switches or published a formal implementation schedule.

What the FDA Can Actually Change: Monographs, New Pathways, and Evidence Rules

The FDA has several mechanisms for expanding OTC access, and Makary signaled a faster pace in 2026. The agency can update OTC monographs and use newer frameworks that allow nonprescription use under defined “additional conditions,” rather than forcing a one-size-fits-all approach.

Recent statutory and funding developments, including reauthorizations extending user-fee programs, provide the administrative capacity to run more reviews—but evidence requirements still matter when a product shifts to self-directed use.

That evidence question is where prior efforts ran into trouble. Past attempts to move certain drug classes over the counter, including efforts involving statins, faced concerns about whether consumers can properly self-select, follow instructions, and know when to seek medical care.

The research reflects that Makary’s proposal is broader than incremental switches of the past, meaning the FDA may have to prove—drug by drug—that convenience doesn’t come at the cost of preventable harm.

Industry Pushback Focuses on Cost-Shifting and Safety, Not Just Regulation

Opposition described in the research is not limited to generic-versus-brand politics; it centers on who pays and how patients use medications. Trade groups representing generic manufacturers and brand-name companies warned that mass switches could leave many patients paying entirely out of pocket, especially if insurers refuse to cover OTC products.

They also argued that pricing should not drive regulatory decisions and urged consultation with manufacturers to avoid destabilizing coverage and supply.

Those concerns are not automatically partisan, but they intersect with a reality many families already feel: health care “reform” often morphs into cost-shifting. If a medicine moves OTC and insurance coverage drops, a middle-class household may face higher upfront costs even if the list price falls.

The research does not provide projected savings or cost increases, so the financial impact will likely depend on insurer behavior, PBM responses, and whether competition truly pushes shelf prices down.

Enforcement on Copycats Shows the Other Side of Deregulation: Drawn Lines Still Matter

Makary’s OTC vision is paired with a separate enforcement posture on products the agency considers illegal or unapproved, including copycat versions of high-demand drugs.

The research cites an early-February 2026 statement highlighting action against mass marketing of copycat GLP-1 products, underscoring that “less red tape” is not the same as “anything goes.” For conservatives wary of government picking winners and losers, consistency will be judged by clear rules applied evenly.

For now, the bottom line is that Makary’s comments signal a philosophical shift—patient autonomy first, prescriptions reserved for genuine risk—while the practical details remain unsettled.

The FDA still must choose which categories qualify as “basic” and “safe,” define what monitoring is necessary, and avoid unintended coverage fallout. Limited public detail is available on the first wave of candidates beyond general examples, so the next concrete indicator will be formal FDA actions and published criteria.